Antioxidant treatment ameliorates experimental diabetes-induced depressive-like behaviour and reduces oxidative stress in brain and pancreas

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 3, 2016, Pages 278-288

  Réus, Gislaine Z ^a,b   dos Santos, Maria Augusta B ^a   Abelaira, Helena M ^a   Titus, Stephanie E ^b   Carlessi, Anelise S ^a   Matias, Beatriz I ^a   Bruchchen, Livia ^a   Florentino, Drielly ^c   Vieira, Andriele ^c   Petronilho, Fabricia ^c   Ceretta, Luciane B ^a   Zugno, Alexandra I ^a   Quevedo, João ^a,b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

Antioxidants; Deferoxamine; Diabetes; Major depressive disorder; N acetylcysteine; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALLOXAN; CARBONYL DERIVATIVE; CATALASE; DEFEROXAMINE; LIPID; SUPEROXIDE DISMUTASE; ANTIOXIDANT; SCAVENGER; SIDEROPHORE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIOR CHANGE; BRAIN; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ENZYME ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; HIPPOCAMPUS; LONG TERM CARE; MALE; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATIVE STRESS; PANCREAS; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; WISTAR RAT; ANIMAL; ANIMAL BEHAVIOR; DEPRESSIVE DISORDER; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; LIPID PEROXIDATION; METABOLISM; PATHOLOGY; PSYCHOLOGY;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; DEFEROXAMINE; DEPRESSIVE DISORDER; DIABETES MELLITUS, EXPERIMENTAL; FREE RADICAL SCAVENGERS; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PANCREAS; RATS; RATS, WISTAR; SIDEROPHORES;

EID: 84959574642     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2732     Document Type: Article

References (51)

1. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2007; 1: S1-S103.
2. Robles GI, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 2009; 21: 219-240.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
4. Ceretta LB, Réus GZ, Abelaira HM, et al. Increased prevalence of mood disorders and suicidal ideation in type 2 diabetic patients. Acta Diabetol 2012a; 49(Suppl 1): S227-S234.
5. Santos MA, Ceretta LB, Réus GZ, et al. Anxiety disorders are associated with quality of life impairment in patients with insulin-dependent type 2 diabetes: a case-control study. Rev Bras Psiquiatr 2014; 36: 298-304.
6. Sharma AN, Bauer IE, Sanches M, et al. Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation. Prog Neuropsychopharmacol Biol Psychiatry 2014; 54: 289-298.
7. Abelaira HM, Réus GZ, Petronilho F, Barichello T, Quevedo J. Neuroimmunomodulation in depression: a review of inflammatory cytokines involved in this process. Neurochem Res 2014; 39: 1634-1639.
8. Ceretta LB, Réus GZ, Abelaira HM, et al. Increased oxidative stress and imbalance in antioxidant enzymes in the brains of alloxan-induced diabetic rats. Exp Diabetes Res 2012b; 2012: 302682.
9. Ceretta LB, Réus GZ, Stringari RB, et al. Imipramine treatment reverses depressive-like behavior in alloxan-diabetic rats. Diabetes Metab Res Rev 2012c; 28: 139-144.
10. Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell 2015; 160: 816-827.
11. Réus GZ, Nacif MP, Abelaira HM, et al. Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation. Neurosci Lett 2015a; 584: 83-87.
12. Réus GZ, Abelaira HM, Maciel AL, et al. Minocycline protects against oxidative damage and alters energy metabolism parameters in the brain of rats subjected to chronic mild stress. Metab Brain Dis 2015b; 30: 545-553.
13. Chen H, Li X, Epstein PN. MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. Diabetes 2005; 54: 1437-1446.
14. Lepore DA, Shinkel TA, Fisicaro N, et al. Enhanced expression of glutathione peroxidase protects islet beta cells from hypoxia-reoxygenation. Xenotransplantation 2004; 11: 53-59.
15. Rachek LI, Thornley NP, Grishko VI, LeDoux SP, Wilson GL. Protection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria. Diabetes 2006; 55: 1022-1028.
16. Arent CO, Réus GZ, Abelaira HM, et al. Synergist effects of N-acetylcysteine and deferoxamine treatment on behavioral and oxidative parameters induced by chronic mild stress in rats. Neurochem Int 2012; 61: 1072-1080.
17. Della FP, Abelaira HM, Réus GZ, et al. Tianeptine exerts neuroprotective effects in the brain tissue of rats exposed to the chronic stress model. Pharmacol Biochem Behav 2012; 103: 395-402.
18. Nunomura A, Tamaoki T, Motohashi N. Role of oxidative stress in the pathophysiology of neuropsychiatric disorders. Seishin Shinkeigaku Zasshi 2014; 116: 842-858.
19. Réus GZ, Carlessi AS, Titus SE, et al. A single dose of S-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation. Dev Neurobiol 2015c in press.
20. Köse SA, Naziroğlu M. N-Acetyl cysteine reduces oxidative toxicity, apoptosis, and calcium entry through TRPV1 channels in the neutrophils of patients with polycystic ovary syndrome. Free Radic Res 2015; 9: 1-9.
21. Rapucci Moraes LH, Bollineli RC, Mizobuti DS, Dos Reis Silveira L, Marques MJ, Minatel E. Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells. Redox Rep 2014 in press.
22. Gamage AM, Lee KO, Gan YH. Effect of oral N-acetyl cysteine supplementation in type 2 diabetic patients on intracellular glutathione content and innate immune responses to Burkholderia pseudomallei. Microbes Infect 2014; 16: 661-671.
23. Genet S, Kale RK, Baquer NZ. Effects of free radicals on cytosolic creatine kinase activities and protection by antioxidant enzymes and sulfhydryl compounds. Mol Cell Biochem 2000; 210: 23-28.
24. Najafi R, Sharifi AM. Deferoxamine preconditioning potentiates mesenchymal stem cell homing in vitro and in streptozotocin-diabetic rats. Expert Opin Biol Ther 2013; 13: 959-972.
25. Ribeiro G, Roehrs M, Bairros A, et al. N-Acetylcysteine on oxidative damage in diabetic rats. Drug Chem Toxicol 2011; 34: 467-474.
26. Behr GA, da Silva EG, Ferreira AR, Cerski CT, Dal-Pizzol F, Moreira JC. Pancreas beta-cells morphology, liver antioxidant enzymes and liver oxidative parameters in alloxan-resistant and alloxan-susceptible Wistar rats: a viable model system for the study of concepts into reactive oxygen species. Fundam Clin Pharmacol 2008; 22: 657-666.
27. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001; 50: 537-546.
28. Paxinos G, Watson C. The rat brain: stereotaxic coordinates (2nd edn). Academic Press: Australia, 1986.
29. Pouraboli I, Nazari S, Sabet N, Sharififar F, Jafari M. Antidiabetic, antioxidant, and antilipid peroxidative activities of Dracocephalum polychaetum shoot extract in streptozotocin-induced diabetic rats: in vivo and in vitro studies. Pharm Biol 2015; 22: 1-7.
30. Berk M, Dean OM, Cotton SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75: 628-636.
31. Carvalho AF, Macêdo DS, Goulia P, Hyphantis TN. N-Acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression. J Clin Psychopharmacol 2013; 33: 719-720.
32. Oloyede HO, Bello TO, Ajiboye TO, Salawu MO. Antidiabetic and antidyslipidemic activities of aqueous leaf extract of Dioscoreophyllum cumminsii (Stapf) Diels in alloxan-induced diabetic rats. J Ethnopharmacol 2015; 166: 313-322.
33. Pitocco D, Zaccardi F, Di Stasio E, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud 2010; 7: 15-25.
34. Ceretta LB, Réus GZ, Rezin GT, Scaini G, Streck EL, Quevedo J. Brain energy metabolism parameters in an animal model of diabetes. Metab Brain Dis 2010; 25: 391-396.
35. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BW. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 2015; 51: 164-175.
36. Lucca G, Comim CM, Valvassori SS, et al. Effects of chronic mild stress on the oxidative parameters in the rat brain. Neurochem Int 2009a; 54: 358-362.
37. Lucca G, Comim CM, Valvassori SS, et al. Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm. J Psychiatr Res 2009b; 43: 864-869.
38. Tang ZJ, Zou W, Yuan J, et al. Antidepressant-like and anxiolytic-like effects of hydrogen sulfide in streptozotocin-induced diabetic rats through inhibition of hippocampal oxidative stress. Behav Pharmacol 2015 in press.
39. Berk M, Copolov DL, Dean O, et al. N-Acetyl cysteine for depressive symptoms in bipolar disorder: a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-475.
40. Magalhaes PV, Dean OM, Bush AI, et al. N-Acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011; 33: 374-378.
41. Chen G, Shi J, Hu Z, Hang C. Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. Mediators Inflamm 2008; 2008: 716458.
42. Dean O, Giorlando F, Berk M. N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36: 78-86.
43. Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol Med 1989; 7: 645-651.
44. Valvassori SS, Petronilho FC, Reus GZ, et al. Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1064-1068.
45. Kamboj SS, Sandhir R. Protective effect of N-acetylcysteine supplementation on mitochondrial oxidative stress and mitochondrial enzymes in cerebral cortex of streptozotocin-treated diabetic rats. Mitochondrion 2011; 11: 214-222.
46. Kamboj SS, Chopra K, Sandhir R. Hyperglycemia-induced alterations in synaptosomal membrane fluidity and activity of membrane bound enzyme: beneficial effect of N-acetylcysteine supplementation. Neuroscience 2009; 162: 349-358.
47. Moazzen H, Lu X, Ma NL, et al. N-Acetylcysteine prevents congenital heart defects induced by pregestational diabetes. Cardiovasc Diabetol 2014; 13: 46.
48. Pittenger C, Duman R. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88-109.
49. Reus GZ, Abelaira HM, Leffa DD, Quevedo J. Cognitive dysfunction in depression: lessons learned from animal models. CNS Neurol Disord Drug Targets 2014; 13: 1860-1870.
50. Bornstein NM, Brainin M, Guekht A, Skoog I, Korczyn AD. Diabetes and the brain: issues and unmet needs. Neurol Sci 2014; 35: 995-1001.
51. Michel TM, Thome J, Martin D, et al. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm 2004; 111: 1191-1201.